Class summary at a glance.

Every drug in the RANK Ligand Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $1.26Bcombined across class
Total Rx claims: 699K508K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Denosumab

Brand: BILDYOS · 699K Part D claims (CY24) · 508K beneficiaries · First FDA approval: 2010-06-05

Brand-only (no generics) 524 plans require PA

Low NADAC$1535.81

→

Avg plan cost$1853.35

Part D spend $1.26B 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Denosumab-Bmwo

Brand: Osenvelt · — Part D claims (CY24) · First FDA approval: 2025-07-02

Brand-only (no generics) 152 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Denosumab-Kyqq

Brand: AUKELSO · — Part D claims (CY24) · First FDA approval: 2026-01-05

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Denosumab-Mobz

Brand: Boncresa · — Part D claims (CY24) · First FDA approval: 2025-12-23

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Denosumab-Qbde

Brand: ENOBY · — Part D claims (CY24) · First FDA approval: 2026-01-08

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.